Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.207
https://www.valueinhealthjournal.com/article/S1098-3015(17)30541-7/fulltext
Title :
Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30541-7&doi=10.1016/j.jval.2017.08.207
First page :
A434
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
187